GRAM Completes Fourth FDA Inspection
GRAM completed a fourth FDA inspection of its parenteral manufacturing facility with no Form 483 observation issues.
Grand River Aseptic Manufacturing (GRAM) announced on Feb. 10, 2016 the competition of its fourth FDA inspection of its contract parenteral manufacturing facility in Grand Rapids, MI.
The seven-day inspection included a general GMP and a pre-approval inspection. FDA found GRAM to be in compliance with the current good manufacturing practices (cGMP) and passed pre-approval inspection, with no Form 483 observation issues. According to FDA, Form 483 is issued at the conclusion of inspections if the investigators discover violations of the Food Drug and Cosmetic Act and related acts.
GRAM is a parenteral contract manufacturing organization focused on cGMP manufacturing and new product development. The company specializes in preclinical, clinical, and commercial manufacturing.
Source: GRAM
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
